Download PDF

1. Company Snapshot

1.a. Company Description

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.


It has collaboration agreements with F.Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio.The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on SRPT

Breaking News: Sarepta Therapeutics reported a wider Q4 loss, with an adjusted loss of $3.58 per share, missing the Wall Street estimate loss of $1.31. However, sales reached $442.93 million, beating the consensus of $391.92 million. Elevidys sales tumbled, but revenues top estimates. The company provided 2026 guidance outlining a cautious recovery path. CEO is set to leave after a tumultuous year. Sarepta will present new data at the 2026 Muscular Dystrophy Association Clinical & Scientific Congress. A hold recommendation is given by some analysts.

1.c. Company Highlights

2. Sarepta Therapeutics' 2025 Earnings: A Resilient Performance Amidst Challenges

Sarepta Therapeutics reported total revenues of $2.2 billion for 2025, a 16% increase year-over-year, with net product revenue totaling $1.86 billion. The company's actual EPS came out at '-3.58', missing estimates at '-0.71'. The cash balance grew to $954 million, increasing $89 million in the fourth quarter. With a solid financial position, Sarepta is well-positioned to invest in its pipeline and commercial launches.

Publication Date: Mar -01

📋 Highlights
  • Cash Balance Growth:: Cash reserves increased to $954 million, up $89 million in Q4 2025, reflecting strong financial stability.
  • 2025 Net Product Revenue:: Total revenue reached $1.86 billion ($966M PMOs, $899M ELEVIDYS), with Q4 PMO revenue at $259M and ELEVIDYS at $110M.
  • 2026 Revenue Guidance:: Projects $1.2–$1.4 billion in net product revenue, balancing ELEVIDYS cannibalization and PMO stability.
  • Leadership Transition:: CEO Doug Ingram to retire by end-2026, initiating a successor search; PMs highlight 3-year ELEVIDYS data with no treatment-related SAEs.
  • Pipeline Advancements:: Five clinical-stage programs, including siRNA for DM1/FSHD, with Phase III-readiness and $1B+ cash runway for 2026+ investments.

Product Revenue Performance

The company's four approved phosphorodiamidate morpholino oligomers (PMOs) - EXONDYS 51, VYONDYS 53, AMONDYS 45 - have remained stable despite ELEVIDYS cannibalization. Net product revenue for PMOs was $966 million, while ELEVIDYS revenues were $899 million. For 2026, Sarepta expects total net product revenue to be between $1.2 billion and $1.4 billion.

ELEVIDYS Gene Therapy Update

ELEVIDYS, a gene therapy for Duchenne muscular dystrophy, has shown significant disease-modifying benefits despite safety concerns. The company is executing commercial initiatives to address information deficits and increase demand for ELEVIDYS. Sarepta's Chief Commercial Officer, Patrick Moss, emphasized the importance of addressing treatment hesitancy through accurate and clear information.

Pipeline Updates

The company's pipeline includes five clinical-stage programs, including neuromuscular, pulmonary, and CNS programs. Dr. Louise Rodino-Klapac highlighted positive top-line three-year functional results from the EMBARK study of ELEVIDYS, demonstrating statistically significant and clinically meaningful efficacy across key motor function measures.

Valuation Metrics

With a P/S Ratio of 0.8 and an EV/EBITDA of -1.52, Sarepta's valuation metrics indicate that the market is pricing in significant growth expectations. Analysts estimate next year's revenue growth at -14.8%, which may impact the company's valuation. The current valuation multiples suggest that the market is cautious about Sarepta's prospects, but the company's strong pipeline and commercial initiatives may help mitigate this.

Future Prospects

The company's siRNA pipeline, including DM1 and FSHD programs, continues to advance, with Phase I/II studies ongoing. Preliminary data from proof-of-concept studies are expected by the end of the quarter. With a strong financial position and a robust pipeline, Sarepta is well-positioned to drive growth and create value for investors.

3. NewsRoom

Card image cap

Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar -03

Source: seekingalpha.com

Card image cap

Sarepta Therapeutics, Inc. $SRPT Stock Position Lowered by AXQ Capital LP

Feb -27

Source: defenseworld.net

Card image cap

Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates

Feb -26

Source: zacks.com

Card image cap

Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics

Feb -26

Source: zacks.com

Card image cap

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

Feb -26

Source: businesswire.com

Card image cap

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Feb -26

Source: benzinga.com

Card image cap

Sarepta Therapeutics CEO Ingram to retire by year end

Feb -26

Source: reuters.com

Card image cap

Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript

Feb -26

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.93%)

6. Segments

RNA-targeted Therapeutics, Gene Therapy and Other Genetic Therapeutic Modalities

Expected Growth: 13.93%

Sarepta Therapeutics' RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities are driven by increasing demand for rare disease treatments, advancements in gene editing technologies, and a strong pipeline of novel therapies. The company's focus on Duchenne muscular dystrophy and other neuromuscular diseases, as well as its strategic partnerships, contribute to its 13.93% growth.

7. Detailed Products

EXONDYS 51

EXONDYS 51 is a disease-modifying therapy for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

VYONDYS 53

VYONDYS 53 is a disease-modifying therapy for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

AMONDYS 45

AMONDYS 45 is a disease-modifying therapy for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.

8. Sarepta Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Sarepta Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments for muscular dystrophy and other rare genetic diseases.

Bargaining Power Of Customers

Patients and healthcare providers have limited bargaining power due to the rarity of the diseases treated by Sarepta Therapeutics, Inc. and the lack of alternative treatments.

Bargaining Power Of Suppliers

Sarepta Therapeutics, Inc. relies on a few key suppliers for raw materials and manufacturing services, giving them some bargaining power.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative treatments and therapies.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players and new entrants vying for market share and patent protection.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 59.37%
Debt Cost 3.95%
Equity Weight 40.63%
Equity Cost 8.64%
WACC 5.85%
Leverage 146.14%

11. Quality Control: Sarepta Therapeutics, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Blueprint Medicines

A-Score: 5.6/10

Value: 6.0

Growth: 7.1

Quality: 5.2

Yield: 0.0

Momentum: 9.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
SpringWorks Therapeutics

A-Score: 4.3/10

Value: 6.2

Growth: 4.6

Quality: 5.0

Yield: 0.0

Momentum: 8.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Avidity Biosciences

A-Score: 4.2/10

Value: 6.2

Growth: 2.7

Quality: 5.1

Yield: 0.0

Momentum: 10.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Sarepta Therapeutics

A-Score: 3.8/10

Value: 8.7

Growth: 7.9

Quality: 5.1

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Agios Pharmaceuticals

A-Score: 3.2/10

Value: 7.6

Growth: 4.2

Quality: 5.1

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Crinetics Pharmaceuticals

A-Score: 2.8/10

Value: 6.4

Growth: 1.1

Quality: 5.1

Yield: 0.0

Momentum: 1.5

Volatility: 2.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

15.87$

Current Price

15.87$

Potential

-0.00%

Expected Cash-Flows